considerations

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 48/100

   Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025-03-01 · Brain scans and imaging

   Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is anticipated to increase with the introduction of new disease-modifying therapies.

   • Biomarkers
   • Brain Scans
2. 41/100

   Health Economic Considerations in the Deployment of an Alzheimer's Prevention Therapy

   ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The journal of prevention of Alzheimer's disease · 2024-01-01 · Biomarkers

   The program would generate per-person value of $53,721 from a payer (reduction of direct cost and patient QALY gains) and $69,861 from a societal perspective (adding valuation of reduced caregiver burden).

   • Policy
   • Treatments
   • Prevention
3. 52/100

   Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice

   ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022-03-02 · Biomarkers

   Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity.

   • Biomarkers
   • Health Equity
   • Clinical Trials
4. 36/100

   Epigenetic studies in Alzheimer's disease: current findings, caveats, and considerations for future studies

   ✓ Peer-reviewed alzhub usefulness score 36 out of 100. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2013-09-13 · Genetics

   Alzheimer's disease (AD) is a sporadic, chronic neurodegenerative disease, usually occurring late in life.

   • Genetics
5. 36/100

   Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies

   ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Clinical and translational imaging · 2013-08-01 · Brain scans and imaging

   Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder associated with progressive loss of cognitive function. 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has long been used to measure resting-state cerebral metabolic rates of glucose, a proxy for neuronal activity.

   • Brain Scans
   • Genetics
6. 59/100

   Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements

   ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2009-02-17 · Brain scans and imaging

   The 50- to 70-min time window provided a good compromise between physiologic validity, stability, sensitivity, and clinical feasibility across the control, MCI, and AD subject data examined in this study.

   • Brain Scans

All topic tags with their study counts